Researchers at the University of Illinois recently re-engineered small molecules to disrupt toxic RNA repeats involved in DM2.
Researchers identify the gene believed to be responsible for adverse statin drug side effects in DM2 patients.
A recently published study from Sweden reported impaired facial recognition in people with DM1 and indicated that there are brain differences that affect how faces are perceived and stored by people with DM1.
Matthew Disney, PhD, associate professor in the Department of Chemistry at The Scripps Research Institute in Florida, has been working with a talented research team in his lab on a number of projects, including one studying how small molecules may target toxic RNA folds in DM2.
MDF community members often contact the Foundation with questions about genetic testing. We spoke with Carly Siskind of Stanford's Neuromuscular Team about the pros and cons of testing.